The purpose of this study is to determine the effect of gemcabene on the pharmacokinetics of atorvastatin 80 mg
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
20
1x300 mg gemcabene tablets orally once daily (QD) for 11 days
3x300 mg Gemcabene tablets orally once daily (QD) for 11 days
2x40 mg Atorvastatin tablets orally once daily (QD)
Pharmacokinetics
Cmax
Time frame: Days 5, 16 and 27
Pharmacokinetics
Area Under the Curve (AUC)
Time frame: Days 5, 16, and 27
Adverse Events
Time frame: 27 days
Clinical Laboratory - hematology, chemistry, urinalysis
Clinical Laboratory Abnormalities
Time frame: 27 days
ECG
Clinically Significant Changes
Time frame: 27 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.